



ANDA 77-472

Food and Drug Administration
Rockville MD 20857

NOV 1 2006

Ranbaxy Inc.
U.S. Agent for: Ranbaxy Laboratories Limited
Attention: Abha Pant
Executive Director Regulatory Affairs
600 College Road East
Princeton, NJ 08540

Dear Sir or Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 22, 2004, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Cetirizine Hydrochloride Syrup, 5 mg/5 mL.

Reference is also made to your amendment dated September 23, 2005, and January 9, 2006.

We have completed the review of this ANDA, and based upon the information you have presented to date we have concluded that the drug is safe and effective for use as recommended in the submitted labeling. However, we are unable to grant final approval to your ANDA at this time because of the patent issue noted below. Therefore, the ANDA is **tentatively approved**. This determination is based upon information available to the agency at this time (i.e., information in your ANDA and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacturing and testing of the drug product) and is therefore subject to change on the basis of new information that may come to our attention. This letter does not address issues related to the 180-day exclusivity provisions under section 505(j)(5)(B)(iv) of the Act.

The referenced listed drug (RLD) upon which you have based your ANDA, Zyrtec Syrup, 5 mg/5 mL of Pfizer, is subject to a period of patent protection. As noted in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"), U.S. Patent No. 4,525,358 (the '358 patent), is scheduled to expire (with pediatric exclusivity added) on December 25, 2007.

Your ANDA contains a paragraph III certification to the '358 patent under section 505(j)(2)(A)(vii)(III) of the Act stating that Ranbaxy Laboratories Limited will not market Cetirizine Hydrochloride Syrup, 5 mg/5 mL prior to the expiration of the patent. Therefore, final approval of your ANDA may not be made effective pursuant to section 505(j)(5)(B)(ii) of the Act until the '358 patent has expired, currently, December 25, 2007 (with pediatric exclusivity added).

To reactivate your ANDA prior to final approval, please submit a "MINOR AMENDMENT - FINAL APPROVAL REQUESTED" 90 days prior to the date you believe that your ANDA will be eligible for final approval. This amendment should provide the legal/regulatory basis for your request for final approval, and it should also identify changes, if any, in the conditions under which the product was tentatively approved, i.e., updated information such as final-printed labeling, chemistry, manufacturing, and controls data as appropriate. This amendment should be submitted even if none of these changes were made. This amendment should be designated clearly in your cover letter as a "MINOR AMENDMENT - FINAL APPROVAL REQUESTED".

In addition to the amendment requested above, the agency may request at any time prior to the date of final approval that you submit an additional amendment containing the requested information. Failure to submit either or, if requested, both amendments may result in rescission of the tentative approval status of your ANDA, or may result in a delay in the issuance of the final approval letter.


Any significant changes in the conditions outlined in this ANDA as well as changes in the status of the manufacturing and testing facilities' compliance with current good manufacturing practices (CGMPs) are subject to agency review before final approval of the ANDA will be made. Such changes should be submitted as an amendment to the ANDA and categorized as representing either "major" or "minor" changes. The amendment will be reviewed according to OGD policy in effect at the time of receipt. Your submission of multiple amendments prior to final approval may also lead to a delay in the issuance of the final approval letter.

This drug product may not be marketed without final agency approval under section 505 of the Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under section 501 of the Act. Also, until the agency issues the final

approval letter, this drug product will not be deemed approved for marketing under section 505 of the Act, and will not be listed in the Orange Book. Should you believe that there are grounds for issuing the final approval letter prior to December 25, 2007, you should amend your ANDA accordingly.

For further information on the status of this ANDA or upon submitting an amendment to the ANDA, please contact Leigh Ann Matheny, Project Manager, at 301-827-9275.

Sincerely yours,

A handwritten signature in dark ink, appearing to read "Gary Buehler". The signature is written in a cursive style with a large, prominent initial "G".

Gary Buehler

Director

Office of Generic Drugs

Center for Drug Evaluation and Research